Id: acc0827
Group: 2sens
Protein: S6
Gene Symbol: RPS6
Protein Id: P62753
Protein Name: RS6_HUMAN
PTM: phosphorylation
Site: Thr389
Site Sequence: -------------------------------------------------------------------------------------------------------------------------------------------------------
Disease Category: Cancer
Disease: Colorectal Cancer
Disease Subtype: Colon Cancer
Disease Cellline: COLO205
Disease Info:
Drug: trametinib
Drug Info: "Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2, used for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, either as a single agent or in combination with dabrafenib. "
Effect: inhibit
Effect Info: SHR8443 inhibits the phosphorylation of AKT and S6 in tumor tissues and overcomes the resistance to RAF/MEK inhibitors.
Note:
Score: 5.0
Pubmed(PMID): 29296217
Sentence Index:
Sentence:

Sequence & Structure:

MKLNISFPATGCQKLIEVDDERKLRTFYEKRMATEVAADALGEEWKGYVVRISGGNDKQGFPMKQGVLTHGRVRLLLSKGHSCYRPRRTGERKRKSVRGCIVDANLSVLNLVIVKKGEKDIPGLTDTTVPRRLGPKRASRIRKLFNLSKEDDVRQYVVRKPLNKEGKKPRTKAPKIQRLVTPRVLQHKRRRIALKKQRTKKNKEEAAEYAKLLAKRMKEAKEKRQEQIAKRRRLSSLRASTSKSESSQK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
RPS6 ATALUREN 80S Ribosome modulator 4 - Duchenne muscular dystrophy EMA
RPS6 ATALUREN 80S Ribosome modulator 3 Completed Duchenne muscular dystrophy ClinicalTrials
ClinicalTrials
ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 3 Completed cystic fibrosis ClinicalTrials
ClinicalTrials
ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 3 Terminated cystic fibrosis ClinicalTrials
ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 3 Completed Becker muscular dystrophy ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 3 Completed qualitative or quantitative defects of dystrophin ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 3 Enrolling by invitation Duchenne muscular dystrophy ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 3 Terminated Duchenne muscular dystrophy ClinicalTrials
RPS6 MT-3724 80S Ribosome inhibitor 2 Terminated diffuse large B-cell lymphoma ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Completed epilepsy ClinicalTrials
RPS6 MT-3724 80S Ribosome inhibitor 2 Terminated non-Hodgkins lymphoma ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Terminated hemophilia A ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Completed Duchenne muscular dystrophy ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Terminated Duchenne muscular dystrophy ClinicalTrials
ClinicalTrials
ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Completed cystic fibrosis ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
RPS6 ELX-02 80S Ribosome modulator 2 Completed cystic fibrosis ClinicalTrials
ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Terminated Becker muscular dystrophy ClinicalTrials
ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Completed Becker muscular dystrophy ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Terminated hemophilia B ClinicalTrials
RPS6 ELX-02 80S Ribosome modulator 2 Recruiting Alport syndrome ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Completed aniridia ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Withdrawn aniridia ClinicalTrials
RPS6 ELX-02 80S Ribosome modulator 2 Terminated cystinosis ClinicalTrials
RPS6 ATALUREN 80S Ribosome modulator 2 Terminated Disorder of amino acid and other organic acid metabolism ClinicalTrials
RPS6 MT-3724 80S Ribosome inhibitor 1 Terminated neoplasm of mature B-cells ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

RPS6-Ser148
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6-Ser235
Cancer Intensity
BRCA 1.184
COAD
HGSC
ccRCC -0.383
GBM 0.073
HNSC 0.382
LUAD 0.449
LUSC 0.94
non_ccRCC -2.268
PDAC -0.16
UCEC -0.215
RPS6-Ser236
Cancer Intensity
BRCA 1.399
COAD 0.214
HGSC
ccRCC -0.441
GBM 0.023
HNSC 0.338
LUAD 0.407
LUSC 0.907
non_ccRCC -2.362
PDAC -0.214
UCEC -0.27
RPS6-Ser240
Cancer Intensity
BRCA 1.329
COAD -0.99
HGSC 0.145
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC -0.484
UCEC
RPS6-Ser242
Cancer Intensity
BRCA
COAD -0.542
HGSC 1.154
ccRCC
GBM
HNSC -0.612
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6-Ser82
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.321
HNSC -0.485
LUAD -0.564
LUSC 2.03
non_ccRCC
PDAC -0.381
UCEC -0.278
RPS6-Tyr84
Cancer Intensity
BRCA -0.503
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.443
LUSC 1.498
non_ccRCC
PDAC -0.552
UCEC
RPS6KA1-Ser218
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC 0.707
UCEC -0.707
RPS6KA1-Ser230
Cancer Intensity
BRCA
COAD 0.199
HGSC 1.332
ccRCC
GBM
HNSC -0.855
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.676
RPS6KA1-Ser28
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.311
GBM
HNSC
LUAD -0.05
LUSC -1.328
non_ccRCC
PDAC 1.067
UCEC
RPS6KA1-Ser372
Cancer Intensity
BRCA 0.233
COAD -0.684
HGSC 2.371
ccRCC -0.505
GBM 0.694
HNSC -0.745
LUAD -0.088
LUSC 0.644
non_ccRCC -1.42
PDAC -0.202
UCEC -0.296
RPS6KA1-Ser378
Cancer Intensity
BRCA -0.001
COAD -1.356
HGSC
ccRCC -1.574
GBM 1.362
HNSC 1.141
LUAD 0.66
LUSC 0.113
non_ccRCC -0.073
PDAC
UCEC -0.27
RPS6KA1-Ser389
Cancer Intensity
BRCA -0.926
COAD -0.393
HGSC 2.613
ccRCC -0.217
GBM -0.311
HNSC -0.007
LUAD -0.099
LUSC 0.478
non_ccRCC -1.325
PDAC 0.04
UCEC 0.147
RPS6KA1-Ser522
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.791
LUSC
non_ccRCC 1.124
PDAC
UCEC -0.333
RPS6KA1-Ser54
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.476
GBM
HNSC -1.836
LUAD 0.264
LUSC 0.576
non_ccRCC -0.041
PDAC -0.68
UCEC 1.24
RPS6KA1-Ser693
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA1-Ser696
Cancer Intensity
BRCA 0.042
COAD -1.377
HGSC
ccRCC -0.299
GBM 2.161
HNSC -0.573
LUAD -0.925
LUSC -0.023
non_ccRCC 1.027
PDAC 0.212
UCEC -0.244
RPS6KA1-Ser81
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.665
GBM
HNSC
LUAD 0.358
LUSC 0.464
non_ccRCC -1.488
PDAC
UCEC
RPS6KA1-Thr234
Cancer Intensity
BRCA -0.481
COAD -0.141
HGSC 2.489
ccRCC -0.603
GBM -0.123
HNSC 0.098
LUAD -0.085
LUSC 0.818
non_ccRCC -1.463
PDAC -0.584
UCEC 0.076
RPS6KA1-Thr368
Cancer Intensity
BRCA -1.456
COAD 0.005
HGSC
ccRCC -0.039
GBM 0.705
HNSC -1.287
LUAD -0.001
LUSC 1.758
non_ccRCC -0.385
PDAC
UCEC 0.7
RPS6KA1-Thr393
Cancer Intensity
BRCA
COAD -0.738
HGSC 0.361
ccRCC -0.874
GBM
HNSC 1.25
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA1-Thr582
Cancer Intensity
BRCA -0.952
COAD 0.136
HGSC 0.538
ccRCC -0.595
GBM 2.708
HNSC -0.471
LUAD -0.299
LUSC 0.054
non_ccRCC -0.367
PDAC -0.806
UCEC 0.054
RPS6KA1-Thr586
Cancer Intensity
BRCA
COAD -0.066
HGSC 1.854
ccRCC -0.583
GBM
HNSC 0.095
LUAD -0.224
LUSC
non_ccRCC -1.076
PDAC
UCEC
RPS6KA1-Tyr237
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA1-Tyr585
Cancer Intensity
BRCA
COAD -0.524
HGSC 1.411
ccRCC -0.489
GBM 0.03
HNSC 0.273
LUAD 0.909
LUSC
non_ccRCC
PDAC
UCEC -1.61
RPS6KA2-Ser214
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC 0.707
UCEC -0.707
RPS6KA2-Ser385
Cancer Intensity
BRCA
COAD -0.65
HGSC
ccRCC
GBM -0.116
HNSC
LUAD 0.488
LUSC -1.143
non_ccRCC 1.421
PDAC
UCEC
RPS6KA2-Ser389
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 0.707
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA2-Thr230
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.596
HNSC
LUAD -0.205
LUSC 0.928
non_ccRCC
PDAC
UCEC -1.319
RPS6KA2-Thr578
Cancer Intensity
BRCA
COAD -0.881
HGSC
ccRCC
GBM
HNSC
LUAD 1.087
LUSC
non_ccRCC -0.205
PDAC
UCEC
RPS6KA2-Tyr685
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
RPS6KA3-Ser19
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC 0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA3-Ser215
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC 0.707
UCEC -0.707
RPS6KA3-Ser227
Cancer Intensity
BRCA
COAD 0.199
HGSC 1.332
ccRCC
GBM
HNSC -0.855
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.676
RPS6KA3-Ser369
Cancer Intensity
BRCA -0.255
COAD -0.304
HGSC 2.077
ccRCC -0.493
GBM 0.043
HNSC -0.148
LUAD -0.202
LUSC 1.061
non_ccRCC -2.014
PDAC 0.193
UCEC 0.044
RPS6KA3-Ser375
Cancer Intensity
BRCA -2.039
COAD 0.872
HGSC
ccRCC 0.187
GBM -0.227
HNSC 0.737
LUAD 0.914
LUSC 0.448
non_ccRCC -1.469
PDAC 0.502
UCEC 0.074
RPS6KA3-Ser386
Cancer Intensity
BRCA -0.989
COAD -0.384
HGSC
ccRCC -0.448
GBM -0.368
HNSC 0.525
LUAD 0.047
LUSC 0.227
non_ccRCC -0.822
PDAC -0.324
UCEC 2.535
RPS6KA3-Ser396
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC -0.707
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA3-Ser415
Cancer Intensity
BRCA -2.52
COAD 0.206
HGSC 1.033
ccRCC 0.431
GBM 0.057
HNSC 0.342
LUAD 0.285
LUSC 0.06
non_ccRCC 0.766
PDAC 0.491
UCEC -1.15
RPS6KA3-Ser715
Cancer Intensity
BRCA -0.161
COAD 0.129
HGSC 1.234
ccRCC 0.088
GBM -0.371
HNSC 1.479
LUAD -2.181
LUSC 0.783
non_ccRCC 0.161
PDAC -0.452
UCEC -0.709
RPS6KA3-Ser78
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.665
GBM
HNSC
LUAD 0.358
LUSC 0.464
non_ccRCC -1.488
PDAC
UCEC
RPS6KA3-Thr231
Cancer Intensity
BRCA -0.48
COAD -0.14
HGSC 2.49
ccRCC -0.603
GBM -0.122
HNSC 0.09
LUAD -0.084
LUSC 0.819
non_ccRCC -1.463
PDAC -0.583
UCEC 0.077
RPS6KA3-Thr365
Cancer Intensity
BRCA -0.677
COAD -0.279
HGSC 2.645
ccRCC -0.354
GBM -0.114
HNSC -0.074
LUAD -0.24
LUSC 0.427
non_ccRCC -1.44
PDAC -0.006
UCEC 0.112
RPS6KA3-Thr577
Cancer Intensity
BRCA -0.952
COAD 0.136
HGSC 0.538
ccRCC -0.595
GBM 2.708
HNSC -0.471
LUAD -0.299
LUSC 0.054
non_ccRCC -0.367
PDAC -0.806
UCEC 0.054
RPS6KA3-Thr581
Cancer Intensity
BRCA
COAD -0.066
HGSC 1.854
ccRCC -0.583
GBM
HNSC 0.095
LUAD -0.224
LUSC
non_ccRCC -1.076
PDAC
UCEC
RPS6KA3-Tyr234
Cancer Intensity
BRCA 0.971
COAD 0.41
HGSC -0.822
ccRCC 0.314
GBM
HNSC 0.834
LUAD 0.151
LUSC -0.301
non_ccRCC -2.209
PDAC 0.653
UCEC
RPS6KA3-Tyr580
Cancer Intensity
BRCA
COAD -0.524
HGSC 1.411
ccRCC -0.489
GBM 0.03
HNSC 0.273
LUAD 0.909
LUSC
non_ccRCC
PDAC
UCEC -1.61
RPS6KA4-Ser196
Cancer Intensity
BRCA
COAD 0.707
HGSC
ccRCC
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA4-Ser324
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC -0.707
PDAC
UCEC
RPS6KA4-Ser343
Cancer Intensity
BRCA
COAD -0.444
HGSC -0.405
ccRCC -0.939
GBM
HNSC
LUAD 1.655
LUSC
non_ccRCC
PDAC
UCEC 0.133
RPS6KA4-Ser347
Cancer Intensity
BRCA -1.576
COAD -0.393
HGSC -1.669
ccRCC 0.108
GBM 0.057
HNSC 0.923
LUAD 0.922
LUSC 1.571
non_ccRCC -0.416
PDAC 0.466
UCEC 0.008
RPS6KA4-Ser360
Cancer Intensity
BRCA
COAD 0.371
HGSC
ccRCC 0.761
GBM
HNSC
LUAD -1.132
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA4-Ser427
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.084
GBM
HNSC -0.889
LUAD -0.799
LUSC 1.602
non_ccRCC
PDAC 0.002
UCEC
RPS6KA4-Ser628
Cancer Intensity
BRCA 1.139
COAD
HGSC
ccRCC
GBM
HNSC -0.541
LUAD 0.271
LUSC 0.457
non_ccRCC 0.397
PDAC -1.723
UCEC
RPS6KA4-Ser666
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA4-Ser672
Cancer Intensity
BRCA
COAD -0.511
HGSC 1.497
ccRCC -0.415
GBM
HNSC -0.571
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA4-Ser675
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.151
GBM
HNSC -1.067
LUAD 0.916
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA4-Ser676
Cancer Intensity
BRCA
COAD -0.555
HGSC 2.167
ccRCC -0.537
GBM 0.178
HNSC -0.397
LUAD -0.149
LUSC
non_ccRCC
PDAC
UCEC -0.707
RPS6KA4-Ser715
Cancer Intensity
BRCA 2.005
COAD 0.871
HGSC
ccRCC 0.372
GBM 0.047
HNSC -0.041
LUAD -0.146
LUSC -0.063
non_ccRCC -0.639
PDAC -0.59
UCEC -1.816
RPS6KA4-Ser731
Cancer Intensity
BRCA 0.181
COAD
HGSC 2.352
ccRCC -0.05
GBM
HNSC -0.665
LUAD -0.521
LUSC
non_ccRCC -0.303
PDAC -0.24
UCEC -0.754
RPS6KA4-Ser739
Cancer Intensity
BRCA -0.305
COAD -0.318
HGSC 2.006
ccRCC -0.002
GBM -1.495
HNSC -0.449
LUAD -0.039
LUSC 0.281
non_ccRCC 1.522
PDAC -0.26
UCEC -0.939
RPS6KA4-Thr22
Cancer Intensity
BRCA 0.583
COAD 0.096
HGSC 2.1
ccRCC 0.142
GBM
HNSC -0.848
LUAD -0.29
LUSC -0.293
non_ccRCC
PDAC 0.036
UCEC -1.526
RPS6KA4-Thr681
Cancer Intensity
BRCA 0.185
COAD -0.107
HGSC 2.543
ccRCC -0.339
GBM 0.659
HNSC -0.152
LUAD -0.452
LUSC -0.578
non_ccRCC 0.101
PDAC -1.494
UCEC -0.366
RPS6KA4-Thr733
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA4-Tyr532
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC -0.707
RPS6KA5-Ser176
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
RPS6KA5-Ser340
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KA5-Ser448
Cancer Intensity
BRCA 1.483
COAD
HGSC
ccRCC -0.363
GBM
HNSC
LUAD -0.413
LUSC -0.707
non_ccRCC
PDAC
UCEC
RPS6KA5-Thr216
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.791
GBM
HNSC
LUAD -1.124
LUSC 0.333
non_ccRCC
PDAC
UCEC
RPS6KA5-Thr38
Cancer Intensity
BRCA 0.5
COAD
HGSC
ccRCC
GBM 0.303
HNSC
LUAD 1.047
LUSC -0.272
non_ccRCC
PDAC
UCEC -1.578
RPS6KB1-Ser371
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC 0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB1-Ser375
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB1-Ser418
Cancer Intensity
BRCA -0.189
COAD 0.616
HGSC 1.605
ccRCC -2.354
GBM -0.189
HNSC 0.25
LUAD 0.135
LUSC 0.115
non_ccRCC
PDAC -0.404
UCEC 0.416
RPS6KB1-Ser424
Cancer Intensity
BRCA -0.557
COAD 1.149
HGSC 1.838
ccRCC -1.833
GBM 0.084
HNSC 0.253
LUAD -0.453
LUSC -0.048
non_ccRCC
PDAC -0.577
UCEC 0.145
RPS6KB1-Ser429
Cancer Intensity
BRCA -0.199
COAD
HGSC 1.767
ccRCC
GBM -0.531
HNSC
LUAD
LUSC -0.418
non_ccRCC
PDAC
UCEC -0.618
RPS6KB1-Thr376
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB1-Thr389
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB1-Thr421
Cancer Intensity
BRCA -1.122
COAD 1.552
HGSC
ccRCC -1.395
GBM -0.379
HNSC 0.47
LUAD -0.284
LUSC 0.124
non_ccRCC
PDAC -0.319
UCEC 1.351
RPS6KB2-Ser370
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM
HNSC 0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KB2-Ser416
Cancer Intensity
BRCA -2.003
COAD
HGSC
ccRCC 0.431
GBM
HNSC 0.572
LUAD -0.371
LUSC 0.898
non_ccRCC
PDAC -0.221
UCEC 0.694
RPS6KB2-Ser417
Cancer Intensity
BRCA -2.069
COAD -0.427
HGSC
ccRCC 0.592
GBM
HNSC 0.653
LUAD -0.343
LUSC 0.998
non_ccRCC
PDAC -0.185
UCEC 0.782
RPS6KB2-Ser423
Cancer Intensity
BRCA -1.811
COAD 1.399
HGSC
ccRCC -0.01
GBM
HNSC 0.155
LUAD 0.098
LUSC 1.125
non_ccRCC
PDAC -0.534
UCEC -0.421
RPS6KC1-Ser189
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.707
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
RPS6KC1-Ser190
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.727
GBM
HNSC 1.14
LUAD -0.414
LUSC
non_ccRCC
PDAC
UCEC
RPS6KC1-Ser197
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.509
GBM -0.406
HNSC 0.951
LUAD 1.622
LUSC 0.186
non_ccRCC -1.313
PDAC
UCEC -0.53
RPS6KC1-Ser269
Cancer Intensity
BRCA
COAD -0.144
HGSC 0.582
ccRCC
GBM 0.909
HNSC -1.347
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KC1-Ser270
Cancer Intensity
BRCA 1.354
COAD -0.017
HGSC -1.24
ccRCC
GBM
HNSC 0.509
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.608
RPS6KC1-Ser411
Cancer Intensity
BRCA 2.387
COAD 0.436
HGSC 0.167
ccRCC -0.77
GBM -1.192
HNSC -0.814
LUAD -0.221
LUSC -0.385
non_ccRCC 0.888
PDAC 0.138
UCEC -0.634
RPS6KC1-Ser415
Cancer Intensity
BRCA 0.663
COAD 0.316
HGSC -2.558
ccRCC 0.214
GBM -0.255
HNSC -0.484
LUAD 0.596
LUSC 1.244
non_ccRCC 0.509
PDAC 0.314
UCEC -0.56
RPS6KC1-Ser436
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.116
GBM -1.661
HNSC 0.534
LUAD 0.041
LUSC
non_ccRCC
PDAC
UCEC 0.97
RPS6KC1-Ser437
Cancer Intensity
BRCA 1.598
COAD 0.098
HGSC -1.55
ccRCC
GBM -0.185
HNSC
LUAD
LUSC
non_ccRCC -0.01
PDAC
UCEC 0.048
RPS6KC1-Ser449
Cancer Intensity
BRCA
COAD
HGSC -0.636
ccRCC 0.306
GBM -1.295
HNSC
LUAD -0.856
LUSC 1.652
non_ccRCC 0.316
PDAC
UCEC 0.513
RPS6KC1-Ser516
Cancer Intensity
BRCA 1.127
COAD -2.454
HGSC 0.155
ccRCC -0.193
GBM -0.351
HNSC 0.288
LUAD 0.06
LUSC 0.76
non_ccRCC 0.053
PDAC 1.201
UCEC -0.646
RPS6KC1-Ser546
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.38
GBM 1.215
HNSC -0.565
LUAD -1.03
LUSC
non_ccRCC
PDAC
UCEC
RPS6KC1-Ser548
Cancer Intensity
BRCA
COAD
HGSC 0.746
ccRCC
GBM 0.39
HNSC
LUAD
LUSC
non_ccRCC
PDAC -1.136
UCEC
RPS6KC1-Ser570
Cancer Intensity
BRCA
COAD -1.454
HGSC 0.138
ccRCC
GBM 0.639
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.677
RPS6KC1-Ser571
Cancer Intensity
BRCA
COAD -0.88
HGSC 1.435
ccRCC
GBM -0.357
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.198
RPS6KC1-Ser584
Cancer Intensity
BRCA 0.121
COAD -0.189
HGSC 2.94
ccRCC -0.34
GBM -0.228
HNSC -0.123
LUAD -0.757
LUSC -0.42
non_ccRCC -0.449
PDAC -0.372
UCEC -0.184
RPS6KC1-Ser593
Cancer Intensity
BRCA -0.729
COAD 0.654
HGSC
ccRCC -0.146
GBM -0.406
HNSC -0.14
LUAD 0.416
LUSC 1.15
non_ccRCC 0.897
PDAC 0.583
UCEC -2.28
RPS6KC1-Ser596
Cancer Intensity
BRCA -0.352
COAD 0.789
HGSC
ccRCC -0.09
GBM -0.845
HNSC -0.714
LUAD 0.184
LUSC 0.578
non_ccRCC 1.859
PDAC 0.345
UCEC -1.755
RPS6KC1-Ser598
Cancer Intensity
BRCA
COAD 0.707
HGSC
ccRCC -0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPS6KC1-Ser628
Cancer Intensity
BRCA 0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
RPS6KC1-Ser632
Cancer Intensity
BRCA -1.983
COAD 0.095
HGSC -0.579
ccRCC 0.025
GBM 0.599
HNSC -0.658
LUAD 0.178
LUSC 0.157
non_ccRCC 2.186
PDAC 0.212
UCEC -0.232
RPS6KC1-Ser649
Cancer Intensity
BRCA 1.779
COAD 0.743
HGSC
ccRCC -0.775
GBM -0.53
HNSC
LUAD -0.558
LUSC 0.331
non_ccRCC
PDAC
UCEC -0.99
RPS6KC1-Ser652
Cancer Intensity
BRCA
COAD 0.369
HGSC -2.416
ccRCC 0.254
GBM 0.043
HNSC 0.52
LUAD 0.137
LUSC
non_ccRCC
PDAC 0.74
UCEC 0.352
RPS6KC1-Ser655
Cancer Intensity
BRCA 0.283
COAD -0.475
HGSC 2.861
ccRCC -0.544
GBM -0.389
HNSC 0.282
LUAD -0.378
LUSC -0.631
non_ccRCC -0.563
PDAC -0.115
UCEC -0.329
RPS6KC1-Ser750
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.554
HNSC 0.803
LUAD -0.186
LUSC -1.665
non_ccRCC 0.493
PDAC
UCEC
RPS6KC1-Ser860
Cancer Intensity
BRCA -1.779
COAD
HGSC
ccRCC 0.895
GBM 0.318
HNSC -1.037
LUAD -0.903
LUSC 0.988
non_ccRCC 0.45
PDAC 0.918
UCEC 0.15
RPS6KC1-Thr647
Cancer Intensity
BRCA 1.814
COAD
HGSC
ccRCC -0.458
GBM -0.758
HNSC
LUAD -0.475
LUSC 0.526
non_ccRCC
PDAC
UCEC -0.65
RPS6KC1-Thr847
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.772
GBM
HNSC
LUAD 1.13
LUSC -0.357
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - A Focal segmental glomerulosclerosis Phosphorylation 35483522
S 235 D Systemic lupus erythematosus Phosphorylation 34522717
S 235 D Status epilepticus Phosphorylation 32833881
S 236 D Status epilepticus Phosphorylation 32833881
S 236 D Systemic lupus erythematosus Phosphorylation 34522717
S 244 U Liver cancer Phosphorylation 23537100
S 240 U Liver cancer Phosphorylation 23537100
- - U Ehrlich ascites tumor Phosphorylation 208946
- - U Renal cancer/carcinoma Phosphorylation 16247451
- - U Esophageal squamous cell carcinoma Phosphorylation 22996377
- - U Bladder cancer Phosphorylation 23273076
S 244 U Tuberous sclerosis complex Phosphorylation 17671177
S 240 U Tuberous sclerosis complex Phosphorylation 17671177
S 236 U Non-small cell lung cancer Phosphorylation 35596155
S 236 U Kaposi's sarcoma Phosphorylation 21819957
S 235 U Non-small cell lung cancer Phosphorylation 35596155
S 235 U Kaposi's sarcoma Phosphorylation 21819957

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: